

# Annellation of Baylis–Hillman derivatives: synthesis of highly functionalised tetrahydronaphthalenes

Asma J'mour and Farhat Rezgui\*

Laboratoire de Chimie Organique, Faculté des Sciences de Tunis, Campus Universitaire 2092 Tunis, Tunisia

PTSA-promoted Robinson annellation of  $\alpha$ -(3-oxobutyl)cyclohex-2-en-1-one derivatives in refluxing toluene, affords efficiently in a *one pot* process a variety of hydroxytetrahydronaphthyl carbonyl compounds in good yields. Further highly regioselective electrophilic bromination of these intermediates gave the corresponding bromide derivatives in 92–97% yield.

**Keywords:** Baylis–Hillman alcohols, tetrahydronaphthyl carbonyl compounds, Robinson annellation, electrophilic bromination, regioselectivity

Hydroxyaryl carbonyl compounds are useful intermediates in organic chemistry and for the preparation of biologically active targets.<sup>1</sup> These versatile derivatives are commonly prepared from the Fries rearrangement of aryl esters in the presence of Lewis acids such as aluminium(III) chloride,<sup>2,3</sup> titanium(III) chloride<sup>4–6</sup> or zirconium(III) chloride.<sup>7</sup> Unfortunately, in many cases, this protocol furnished a mixture of regioisomers together with side-products.<sup>8–10</sup> Therefore, intense efforts have been undertaken either to improve the regioselectivity of the Fries rearrangement<sup>11</sup> or to develop new approaches towards this important class of compounds.<sup>12</sup>

Furthermore, in our previous papers,<sup>13,14</sup> starting from  $\alpha$ -(3-oxobutyl)cyclohex-2-en-1-one derivatives **1** in basic conditions, we have described two synthetic routes (i) or (ii) to a new series of bicyclic dienones **2** (Scheme 1).

In continuation of our study on the intramolecular aldol condensation of multifunctional derivatives **1**, we report here their use as intermediates in a simple synthetic method for hydroxy-5,6,7,8-tetrahydronaphthyl carbonyl compounds (THN) **3**. We also disclosed a general procedure for highly regioselective electrophilic bromination of these aryl carbonyl derivatives **3**, yielding a new series of potential intermediates **4** for AMP deaminase inhibitors.<sup>15,16</sup>

## Results and discussion


During our investigation on Robinson annellation of 1,5-dicarbonyl compounds **1** in acidic conditions, we first found that intramolecular aldol reaction of compound **1a** and a catalytic amount (0.1 equiv.) of PTSA (*p*-toluene sulfonic acid) proceeded rapidly in refluxing toluene, affording cleanly in a straightforward process the single hydroxyaryl ketone **3a** in 90% yield (Scheme 2).

Concerning the mechanistic aspect of this reaction, we assume that the present protocol proceeded in a three-step reaction sequence including (i) Robinson annellation-crotonisation giving **1**, that underwent further tautomerisation (ii) and (iii) aromatisation, affording hydroxytetrahydronaphthyl ketone **3a** in good yield (Scheme 3).


The spectroscopic data of **3a** are in agreement with those of literature.<sup>12,17</sup>

Using the optimal cyclisation conditions (0.1 equiv of PTSA in refluxing toluene) previously established for the preparation of **3a**, we then examined the access to its analogous derivatives **3b–d**. During our study, we similarly observed that a one pot three-step reaction proceeded smoothly to give regioselectively and in good yields the corresponding THN **3b–d** (Scheme 2, Table 1).

Note that in contrast to our previous communications on  $K_2CO_3$ -promoted intramolecular cyclisation of compounds **1** into bicyclic dienones **2**<sup>13,14</sup> (Scheme 1), the present procedure



**Scheme 1** Annellation of compounds **1** in basic conditions.



**Scheme 2** PTSA-catalysed annellation of 1,5-diketones **1**.

describes their acidic Robinson annellation into functionalised THN **3**, however, without further deacylation reactions.

In the literature,<sup>15,16</sup> bromohydroxytetrahydronaphthyl carbonyl compounds **3** are described as potential precursors, *via* their corresponding homobenzylic bromide derivatives **5**, for potent inhibitors **6** of adenosine deaminase (Scheme 4).

Treatment of compound **3d** with bromine in acetic acid, we first prepared through a highly regioselective electrophilic bromination, the single bromohydroxynaphthyl ester **4d** in excellent yield (Scheme 5, Table 2).

The crystalline structure of compound **4d**,<sup>18,19</sup> confirmed the preferential attack at the *ortho* position to the hydroxyl group of **3d**. This interesting regioselectivity is in agreement with the fact that the hydroxyl group is a strongly activating *o*- (exclusively available here), *p*-directing substituent.

This simple, efficient procedure (*e.g.*  $Br_2$  in  $AcOH$ ) has been also applied to perform the electrophilic bromination of hydroxytetrahydronaphthyl carbonyl compounds **3a–c**. As seen in Table 2, we have successfully and cleanly prepared the corresponding bromide derivatives **4a–c** in 92–97% yield.


**Table 1** PTSA-catalysed annellation of 1,5-diketones **1**

<b>3</b>	<b>a</b>	<b>b</b>	<b>c</b>	<b>d</b>
R	Me	Ph	OMe	OEt
Yield (%)	90	91	75	82

**Table 2** Electrophilic bromination of compounds **3**


<b>4</b>	<b>a</b>	<b>b</b>	<b>c</b>	<b>d</b>
R	$CH_3$	Ph	OMe	OEt
Yield/%	97	92	92	96

\* Correspondent. E-mail: rez\_far@yahoo.fr




i: Robinson annelation-crotonisation, ii: tautomerisation, iii: aromatisation

**Scheme 3** A plausible reaction mechanism of PTSA-catalysed annelation of compound **1**.



**Scheme 4** Bromide derivatives **4** as useful precursors for inhibitors **6** of adenosine deaminase.



**Scheme 5** Electrophilic bromination of compounds **3**.

## Conclusions

The present work describes PTSA-promoted Robinson annelation of 2-(3-oxobutyl)cyclohex-2-en-1-one derivatives **1** in refluxing toluene to give, via an efficient tandem reactions sequence, a variety of THN **3** which were further subjected to electrophilic bromination conditions in acetic acid, to afford in good yields and in high regioselectivity the corresponding bromohydroxynaphthyl derivatives **4** as useful intermediates for the synthesis of AMP deaminase inhibitors.

## Experimental

### General

<sup>1</sup>H NMR spectra were recorded in CDCl<sub>3</sub> solutions at 300 MHz with tetramethylsilane as internal reference. <sup>13</sup>C NMR spectra were recorded at 75 MHz with CDCl<sub>3</sub> as internal reference. Chemical shifts are given in ppm (δ) and coupling constants *J* are reported in Hz. IR spectra were obtained on a Perkin Elmer Paragon 1000 PC IR spectrometer. Mass spectra were measured on a Hewlett-Packard 5890 spectrometer at 70 eV (EI). Column chromatography was performed using silica gel 60 (70–230 mesh).

### Typical procedure for the preparation of tetrahydronaphthyl carbonyl compounds **3a–d**

A mixture of 2-(3-oxobutyl)cyclohex-2-en-1-one **1** (2 mmol),<sup>13</sup> a catalytic amount (0.1 equiv.) of PTSA and 5 mL of toluene, was refluxed for 2 h. The reaction mixture was diluted with dichloromethane (20 mL) and washed successively with saturated aqueous NaHCO<sub>3</sub> and with brine. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>. After evaporation of the solvents, the product was purified by a column chromatography (ether/petroleum ether: 5/95).

**1-(3-Hydroxy-5,6,7,8-tetrahydro-2-naphthyl)ethanone (3a):** A known compound.<sup>17</sup> M.p. 71 °C (lit.<sup>17</sup>: m.p. 71–72 °C); yield (90%). IR (CHCl<sub>3</sub>): 3673, 1639 cm<sup>-1</sup>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 11.98 (s, 1H), 7.40 (s, 1H), 6.67 (s, 1H), 2.78–2.72 (m, 4H), 2.63 (s, 3H), 1.81–1.74 (m, 4H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 203.9, 159.8, 147.4, 130.8, 127.8, 117.9, 117.5, 29.9, 28.5, 26.5, 23.1, 22.6. MS (EI, 70 eV); *m/z* (%): 147 (15), 175 (100), 190 (M<sup>+</sup>, 43). HRMS Calcd for C<sub>12</sub>H<sub>14</sub>O<sub>2</sub> 190.0994. Found 190.0994.

**1-(3-Hydroxy-5,6,7,8-tetrahydro-2-naphthyl)phenylmethanone (3b):** Yellow oil; yield (91%). IR (CHCl<sub>3</sub>): 3684, 1632 cm<sup>-1</sup>.

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 11.81 (s, 1H), 7.66–7.45 (m, 5H), 7.25 (s, 1H), 6.76 (s, 1H), 2.77–2.75 (m, 2H), 2.63–2.61 (m, 2H), 1.77–1.73 (m, 4H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 201.1, 160.7, 147.4, 138.2, 133.6, 131.5, 129.0, 128.2, 127.7, 117.6, 117.3, 30.0, 28.5, 23.1, 22.6. HRMS Calcd for C<sub>17</sub>H<sub>16</sub>O<sub>2</sub> 252.1150. Found 252.1150.

**Methyl-3-hydroxy-5,6,7,8-tetrahydronaphthalene-2-carboxylate (3c):** Yellow oil; yield (75%). IR (CHCl<sub>3</sub>): 3219, 1675 cm<sup>-1</sup>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 10.41 (s, 1H), 7.51 (s, 1H), 6.67 (s, 1H), 3.91 (s, 3H), 2.74–2.68 (m, 4H), 1.77–1.76 (m, 4H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 170.5, 158.9, 146.3, 129.8, 128.1, 116.9, 110.0, 52.0, 29.8, 28.4, 23.2, 22.7. HRMS Calcd for C<sub>12</sub>H<sub>14</sub>O<sub>3</sub> 206.0943. Found 206.0942.

**Ethyl-3-hydroxy-5,6,7,8-tetrahydronaphthalene-2-carboxylate (3d):** Yellow oil; yield (82%). IR (CHCl<sub>3</sub>): 3674, 3532, 3211, 1671 cm<sup>-1</sup>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 10.52 (s, 1H), 7.51 (s, 1H), 6.65 (s, 1H), 4.36 (q, 2H, *J* = 6.73 Hz), 2.77–2.66 (m, 4H), 1.79–1.74 (m, 4H), 1.40 (t, 3H, *J* = 6.39 Hz). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 170.1, 159.1, 146.0, 129.8, 128.0, 116.8, 110.3, 61.0, 30.0, 28.4, 23.2, 22.7, 14.2. MS (EI, 70 eV); *m/z* (%): 117 (17), 146 (11), 174 (100), 220 (M<sup>+</sup>, 31). HRMS Calcd for C<sub>13</sub>H<sub>16</sub>O<sub>3</sub> 220.1099. Found 220.1099.

### Typical procedure for the preparation of **4a–d**

To a solution of tetrahydronaphthyl carbonyl compounds (2 mmol) **3** in 2 mL of acetic acid, was added dropwise a solution of bromine (2 mmol) in 2 mL of acetic acid under stirring at room temperature. After additional 2 h, the resulting mixture was diluted with water and extracted with dichloromethane. The organic layer was washed with water until neutrality. After usual work up, the residue was purified by a column chromatography (petroleum ether).

**1-(4-Bromo-3-hydroxy-5,6,7,8-tetrahydro-2-naphthyl)ethanone (4a):** M.p. 142 °C; yield (97%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 12.78 (s, 1H), 7.38 (s, 1H), 2.78–2.70 (m, 4H), 2.67 (s, 3H), 1.83–1.72 (m, 4H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 203.8, 156.4, 146.2, 129.5, 129.3, 117.9, 114.3, 31.3, 29.4, 26.5, 22.7, 22.5. MS (EI, 70 eV); *m/z* (%): 115 (26), 117 (12), 145 (16), 146 (27), 253 (100), 255 (97), 268 (M<sup>+</sup>, 66). HRMS Calcd for C<sub>12</sub>H<sub>13</sub>BrO<sub>2</sub> 268.0099. Found 268.0100.

**1-(4-Bromo-3-hydroxy-5,6,7,8-tetrahydro-2-naphthyl)(phenyl) methanone (4b):** M.p. 121 °C; yield (92%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 12.49 (s, 1H), 7.58–7.38 (m, 5H), 7.18 (s, 1H), 2.75–2.71 (m, 2H), 2.59–2.55 (m, 2H), 1.77–1.59 (m, 4H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 200.8, 157.2, 146.2, 137.6, 132.3, 132.0, 129.1, 128.4, 128.3, 117.4, 114.5, 31.3, 29.6, 22.7, 22.6. MS (EI, 70 eV); *m/z* (%): 77 (79), 105 (80), 253 (58), 255 (53), 329 (82), 330 (M<sup>+</sup>, 96), 331 (MH<sup>+</sup>, 100).

**Methyl-4-bromo-3-hydroxy-5,6,7,8-tetrahydronaphthalene-2-carboxylate (4c):** M.p. 86 °C; yield (92%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 11.13 (s, 1H), 7.42 (s, 1H), 3.85 (s, 3H), 2.70–2.59 (m, 4H), 1.75–1.60 (m, 4H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 170.2, 155.6, 145.2, 129.6, 128.6, 113.6, 110.4, 52.5, 31.2, 29.3, 22.7, 22.5. MS (EI, 70 eV); *m/z* (%): 115 (20), 117 (12), 173 (18), 252 (100), 254 (98), 284 (M<sup>+</sup>, 22). HRMS Calcd for C<sub>12</sub>H<sub>13</sub>BrO<sub>3</sub> 284.0048. Found 284.0049.

*Ethyl-4-bromo-3-hydroxy-5,6,7,8-tetrahydronaphthalene-2-carboxylate (4d)*: M.p. 104°C, yield (96%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 11.32 (s, 1H), 7.51 (s, 1H), 4.39 (q, 2H, *J* = 7.35 Hz), 2.78–2.68 (m, 4H), 1.82–1.70 (m, 4H), 1.41 (t, 3H, *J* = 7.36 Hz). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 170.1, 155.0, 145.0, 129.5, 128.5, 113.6, 110.7, 61.7, 31.2, 29.3, 28.4, 22.7, 14.2. MS (*m/z*); 115 (22), 117 (14), 173 (19), 252 (100), 254 (100), 298 (*M*<sup>+</sup>, 25). HRMS Calcd for C<sub>13</sub>H<sub>15</sub>BrO<sub>3</sub> 298.0205. Found 298.0202.

Received 12 June 2009; accepted 11 September 2009

Paper 09/0637 doi: 10.3184/030823409X12532103537360

Published online: 8 October 2009

## References

- 1 D.J. Crouse, S.L. Hurlbut and M.S. Wheeler, *J. Org. Chem.*, 1981, **46**, 374.
- 2 K. Fries and G. Finck, *Ber. Dtsch. Chem. Ges.*, 1908, **41**, 4271.
- 3 K. Fries and W. Pfaffendorf, *Ber. Dtsch. Chem. Ges.*, 1910, **43**, 212.
- 4 R. Martin and P. Demerseman, *Synthesis*, 1989, 25.
- 5 R. Martin and P. Demerseman, *Synthesis*, 1992, 738.
- 6 V. Rozenberg, T. Danilova, E. Sergeeva, E. Vorontsov, Z. Starikova, K. Lysenko and Y. Belokon, *Eur. J. Org. Chem.*, 2000, 3295.
- 7 D.C. Harroweven and R.F. Dainty, *Tetrahedron Lett.*, 1996, **37**, 7659.
- 8 The original work: A.N. Niyazov, B. Namatov and K. Atlyev, *Izv. Akad. Nauk Turkm SSR. Ser. Fiz.-Tekh., Khim. Geol. Nauk.*, 1974, 62; *Chem. Abstr.*, 1975, **82**, 170275.
- 9 B.M. Trost and M.G. Saulnier, *Tetrahedron Lett.*, 1985, **26**, 123.
- 10 L. Crombie, R.C.F. Jones and C.J. Palmer, *Tetrahedron Lett.*, 1985, **26**, 2933.
- 11 G. Sartori, G. Gasnati and F. Bigi, *J. Org. Chem.*, 1990, **55**, 4371.
- 12 A. Bensari and N.T. Zaveri, *Synthesis*, 2003, 267.
- 13 F. Rezgui and M.M. El Gaïed, *Tetrahedron*, 1997, **53**, 15711.
- 14 F. Rezgui and M.M. El Gaïed, *J. Chem. Res., (S)* 1999, 510.
- 15 E. Chan, S.R. Putt and H.D. Hollis Showalter, *J. Org. Chem.*, 1982, **47**, 3457.
- 16 S.R. Kasibhatla, B.C. Bookser, W. Xiao and M.D. Erion, *J. Med. Chem.*, 2001, **44**, 613.
- 17 C. Bolchi, P. Catalano, L. Fumagalli, M. Gobbi, M. Pallavicini, A. Pedretti, L. Villa, G. Vistoli and E. Valoti, *Bioorg. Med. Chem.*, 2004, **12**, 4937.
- 18 F. Ben Amor, A. Jmour, A. Driss and F. Rezgui, *Acta Crystallogr.*, 2007, **E63**, 03314.
- 19 H. Tawada, H. Natsugari, E. Ishikawa, Y. Sugiyama, H. Ikeda and K. Meguro, *Chem. Pharm. Bull.*, 1995, **43**, 616.